Biopure seeks OK to boost stock sales Biopure Corp. is running out of money -- again. Recent regulatory filings, including one yesterday, show the Cambridge blood-substitute developer seeking the financial flexibility it says it will need to keep operating after January. That's when it expects to use up the \$7 million it raised through a stock sale in September.